Amendments to the Claims:

The following claims will replace all prior versions of the claims in this application (in the unlikely event that no claims follow herein, the previously pending claims will remain):

1-59. (Cancelled).

60. (New) A method of treating a mammal to bring about a weight reduction or reduction in obesity, said method comprising administering to the mammal in need of such treatment a therapeutically effective dosage of a lipid mobilizing agent which is a Zn-α_2-glycoprotein, the polypeptide moiety thereof having the sequence as shown in SEQ ID NO:1.

61. (New) A pharmaceutical composition in unit dosage form suitable for oral, rectal, topical or parenteral administration and comprising:

a pharmaceutically acceptable carrier, diluent or excipient; and

a pharmacologically effective amount of biologically active lipid mobilizing agent which is a Zn-α_2-glycoprotein, the polypeptide moiety thereof having the sequence as shown in SEQ ID NO:1.

62. (New) A pharmaceutical composition as claimed in claim 61, which is an injectable formulation incorporating a carrier in the form of a pharmaceutically acceptable injection vehicle.

63. (New) A method of treating a mammal to bring about a weight reduction or reduction in obesity, said method comprising administering to the mammal in need of such treatment a therapeutically effective dosage of a lipid mobilizing agent having an apparent molecular mass of greater than about 6 kDa, as determined by gel exclusion chromatography, and which is obtained by digesting Zn-α_2-glycoprotein, the polypeptide moiety of which has the sequence shown in SEQ ID NO:1, with the enzyme trypsin.

64. (New) A pharmaceutical composition in unit dosage form suitable for oral, rectal, topical or parenteral administration and comprising:

a pharmaceutically acceptable carrier, diluent or excipient; and

a pharmacologically effective amount of biologically active lipid mobilizing agent having an apparent molecular mass of greater than about 6 kDa, as determined by gel exclusion chromatography, and which is obtained by digesting Zn-α_2-glycoprotein, the polypeptide moiety of which has the sequence shown in SEQ ID NO:1, with the enzyme trypsin.

65. (New) A pharmaceutical composition as claimed in claim 64, which is an injectable formulation incorporating a carrier in the form of a pharmaceutically acceptable injection vehicle.

66. (New) A pharmaceutical composition as claimed in claim 64, wherein the biologically active lipid mobilizing agent has an apparent molecular mass of about 7 kDa.